XML 17 R12.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Business Restructuring Charges
6 Months Ended
Jun. 30, 2011
Business Restructuring Charges [Abstract]  
BUSINESS RESTRUCTURING CHARGES
NOTE 8 — BUSINESS RESTRUCTURING CHARGES
     Business restructuring and facility rationalization activities consist primarily of facility closures and restructuring at Carmel, New York; Corona, California; Groveport, Ohio; Mississauga, Canada and Melbourne, Australia for the six months ended June 30, 2011 as follows (in millions):
                                         
                                    Accrual  
    Balance at                             Balance at  
    December 31,     Charged     Cash     Non-cash     June 30,  
    2010     to Expense     Payments     Adjustments     2011  
Cost of sales
                                       
Severance and retention
  $ 12.9     $ 1.2     $ (3.5 )   $     $ 10.6  
Product transfer costs
    1.4       0.8       (2.1 )           0.1  
Facility decommission costs
    1.6       1.1       (2.6 )           0.1  
Accelerated depreciation
          2.2             (2.2 )      
 
                             
 
    15.9       5.3       (8.2 )     (2.2 )     10.8  
 
                             
Operating expenses
                                       
R&D
    3.1       2.9       (1.2 )           4.8  
Accelerated depreciation — R&D
          0.7             (0.7 )      
Selling, general and administrative
    1.0       1.0       (0.5 )           1.5  
Accelerated depreciation — S,G&A
          0.4             (0.4 )      
 
                             
 
    4.1       5.0       (1.7 )     (1.1 )     6.3  
 
                             
 
                                       
Total restructuring charges
  $ 20.0     $ 10.3     $ (9.9 )   $ (3.3 )   $ 17.1  
 
                             
     Product transfer costs consist of documentation, testing and shipping costs to transfer product to other facilities. Operating expenses include severance and retention. Retention is expensed only to the extent earned by employees. Activity related to our business restructuring and facility rationalization activities is primarily attributable to our Global Generics segment.